Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.

European journal of clinical pharmacology - 1 Apr 2023

Wollmann Birgit M, Størset Elisabet, Kringen Marianne Kristiansen, Molden Espen, Smith Robert L

Abstract excerpt

PURPOSE: Poor metabolizers (PMs) of the highly polymorphic enzyme CYP2D6 are usually at high risk of adverse effects during standard recommended dosing of CYP2D6-metabolized drugs. We studied if the metabolism of solanidine, a dietary compound found in potatoes, could serve as a biomarker predicting the CYP2D6 PM phenotype for precision dosing. METHODS: The study included 839 CYP2D6-genotyped patients who were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 36806969
DOI: 10.1007/s00228-023-03462-y
PMCID: PMC10038974

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prediction of CYP2D6 poor metabolizers by measurements of solanidine and metabolites-a study in 839 patients with known CYP2D6 genotype.PMID 36806969Read ↗

Solanidine is a sensitive and specific dietary biomarker for CYP2D6 activity.Semantic proximity Read ↗

Solanidine analysis during therapeutic drug monitoring revealed rare CYP2D6 poor metabolizer genotype: a case reportSemantic proximity Read ↗

Nutrimetric Validation of Solanidine as Dietary-Derived CYP2D6 Activity Marker In Vivo.Semantic proximity Read ↗

Liquid Chromatography-Tandem Mass Spectrometry Quantification of Diet-Derived CYP2D6 Biomarkers for Clinical Phenotyping in Japanese Subjects.Semantic proximity Read ↗

Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity.Semantic proximity Read ↗

Effect of the NFIB rs28379954 T>C polymorphism on CYP2D6-catalyzed metabolism of solanidine.Semantic proximity Read ↗

An improved cytochrome P450 phenotyping cocktail with a simplified and highly sensitive UHPLC-MS/MS assay in human plasma.Semantic proximity Read ↗

Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.Semantic proximity Read ↗

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.Semantic proximity Read ↗

Estimation of the interindividual variability of cytochrome 2D6 activity from urinary metabolic ratios in the literature.Semantic proximity Read ↗

Prevalence of desloratadine poor metabolizer phenotype in healthy Jordanian males.Semantic proximity Read ↗

CYP2D6 Protein Level Is the Major Contributor to Interindividual Variability in CYP2D6-Mediated Drug Metabolism in Healthy Human Liver Tissue.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.